Form 4: MapLight Director Garnett Receives Equity Awards

MapLight Therapeutics, Inc. Director Timothy John Garnett was granted 6,294 restricted stock units and 25,604 employee stock options on October 27, 2025.

Summary

• Timothy John Garnett, a Director of MapLight Therapeutics, Inc. (MPLT), acquired 6,294 shares of Voting Common Stock through a restricted stock unit (RSU) award.
• Each RSU represents a contingent right to receive one share of voting common stock.
• The RSU award vests 1/4th on October 1, 2026, and 1/16th on each subsequent January 1, April 1, July 1, and October 1, contingent on continued service.
• Mr. Garnett also acquired 25,604 employee stock options with an exercise price of $17 per share.
• The stock options vest 1/4th of the total shares on October 1, 2026, and 1/48th of the total shares each month thereafter, contingent on continued service.
• The employee stock options have an expiration date of October 26, 2035.

Sentiment

Score: 6

Explanation: The filing indicates a routine equity grant to a director, which is generally a positive for corporate governance by aligning interests, but it is not a significant market-moving event.

Positives

• The grant of restricted stock units and stock options to a director aligns management's interests with those of shareholders, incentivizing long-term performance.
• Equity compensation is a standard practice to attract and retain experienced board members.

Risks

• The vesting of both the restricted stock units and employee stock options is subject to the Reporting Person's continued service through each vesting date, meaning the awards could be forfeited if service ceases.

Future Outlook

The vesting schedules for the restricted stock units and employee stock options indicate an expectation of continued service from Director Timothy John Garnett through the specified vesting dates, aligning his long-term incentives with the company's performance.

Industry Context

Equity compensation, including restricted stock units and stock options, is a common practice in the biotechnology and pharmaceutical industries to incentivize directors and executives, linking their personal financial success to the company's long-term value creation and shareholder returns.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) and employee stock options for director compensation is a standard practice across the biotech and broader public company landscape, aiming to align director interests with shareholder value.
• Vesting schedules tied to continued service are typical for such awards, ensuring retention and commitment.

Stakeholder Impact

• Shareholders: The equity awards align the director's financial interests with shareholder value, potentially leading to more focused long-term decision-making.
• Employees: The compensation structure for directors can set a precedent or reflect the company's overall approach to equity-based incentives.

Next Steps

• Continued service of Timothy John Garnett through the specified vesting dates for the RSU and option awards.
• Periodic vesting of RSUs on October 1, 2026, and subsequent January 1, April 1, July 1, and October 1 thereafter.
• Monthly vesting of employee stock options starting October 1, 2026.

Key Dates

Keywords

MapLight Therapeutics, MPLT, Timothy John Garnett, Director, Restricted Stock Units, RSU, Stock Options, Equity Compensation, Insider Transaction, Form 4, SEC Filing